IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03474263
Recruitment Status : Not yet recruiting
First Posted : March 22, 2018
Last Update Posted : April 18, 2018
Massachusetts General Hospital
Information provided by (Responsible Party):
Implicit Bioscience

Brief Summary:
Patients with rapidly progressive ALS will be assigned to IC14 intravenously on Day 1-4. This 4-day course will be repeated on Days 8-11. Patients will all undergo MR-PET scans at Massachusetts General Hospital at two time points: before treatment onset and after the last treatment cycle. This scan will measure areas of ALS disease activity and assess response to IC14 treatment. MR-PET scans will be compared to historical controls.

Condition or disease Intervention/treatment Phase
Amyotrophic Lateral Sclerosis Biological: Biologic: IC14 (monoclonal antibody against human CD14) Phase 2

Detailed Description:

This is an open-label, biomarkers-driven study.

Patients with rapidly progressive ALS will be assigned to the following dose regimen of IC14:

• 4 mg/kg intravenously on Day 1, followed by 2 mg/kg daily x 3 days on Days 2-4. This 4-day course will be repeated on Days 8-11.

Patients will be followed for 28 days after the last dose of study drug. Patients will all undergo [11C]-PBR28-MR-PET scans at Massachusetts General Hospital at two time points: before treatment onset and after the last treatment cycle.

Patients will be followed for 28 days after the last dose of study drug for safety.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Open-label Biomarkers-Driven Study Historical controls
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2a, Open-Label Biomarker Study of IC14 for the Treatment of Patients With
Estimated Study Start Date : September 1, 2018
Estimated Primary Completion Date : April 12, 2020
Estimated Study Completion Date : July 12, 2020

Arm Intervention/treatment
Experimental: IC14 (monoclonal anti-CD14 antibody)
Biologic: IC14 (monoclonal anti-CD14 antibody) 4 mg/kg intravenously followed by IC14 2 mg/kg intravenously on Days 2-4. This four-day cycle will be repeated on Days 8-11.
Biological: Biologic: IC14 (monoclonal antibody against human CD14)
IC14 intravenous infusion daily for four days on two successive weeks then MR-PET Scan evaluation for impact on glial activation.
Other Name: Anti-CD14

Primary Outcome Measures :
  1. Glial Activation [ Time Frame: one month ]
    Glial activation measured in the motor region measured by [11C]-PBR28 positron emission tomography (PET). Studies have shown this marker localizes to areas of glial activation and correlates with disease progression and outcomes.

  2. Serum neurofilament [ Time Frame: one month ]
    Serum neurofilament is a biomarker that has been shown to correlate with ALS severity

  3. Urinary p75 neurotrophin receptor [ Time Frame: one month ]
    Urinary p75 neurotrophin receptor is a biomarker that has been shown to correlate with ALS severity

Secondary Outcome Measures :
  1. Safety [ Time Frame: six weeks ]
    Adverse event reporting

  2. Immunogenicity [ Time Frame: six weeks ]
    Human anti-monoclonal antibodies

  3. Pharmacokinetics [ Time Frame: one month ]
    Peak Plasma Concentration (Cmax) of IC14

  4. Pharmacodynamics [ Time Frame: one month ]
    Monocyte CD14 saturation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Capable of providing informed consent and informed consent form signed prior to initiation of any study-specific procedures.
  2. Familial or sporadic ALS defined as clinically possible, probable, or definite by El Escorial Criteria.
  3. Rapidly progressive ALS defined by the Revised ALS Functional Rating Scale (ALSFRS-R) slope ≥1 (48 minus ALSFRS-R score at screening / disease duration in months ≥ 1).
  4. Upper Motor Neuron Burden Score of ≥ 25 (out of 45) at screening
  5. First symptoms of ALS within 3 years of the screening visit
  6. Age between 18 and 80 years at the time of the screening visit.
  7. Not taking riluzole or edaravone or on a stable dose of riluzole or edaravone for at least 3 months prior to screening visit.
  8. Adequate bone marrow reserve, renal and liver function:

    1. absolute neutrophil count ≥ 1500/µL
    2. lymphocyte count < 6000/µL
    3. platelet count ≥ 150,000/µL
    4. hemoglobin ≥ 11 g/dL
    5. creatinine clearance ≥ 60 mL/min
    6. alanine transaminase (ALT) and/or aspartate transaminase (AST) ≤ 3x upper limits of normal (ULN)
    7. total bilirubin ≤ 1.5x ULN
    8. serum albumin ≥ 2.8 g/dL
  9. Females of childbearing potential should be using and committed to continue using one of the following acceptable birth control methods:

    1. Sexual abstinence (inactivity) for 1 month prior to screening through study completion; or
    2. Intrauterine device (IUD) in place for at least 3 months prior to study through study completion; or
    3. Stable hormonal contraception for at least 3 months prior to study through study completion; or
    4. Surgical sterilization (vasectomy) of male partner at least 6 months prior to study.
  10. To be considered of non-childbearing potential, females should be surgically sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be post-menopausal and at least 3 years since last menses.
  11. Males with female partners of childbearing potential must use contraception through study completion.
  12. Ability to safely lie flat for 90 min for magnetic resonance-positron emission tomography (MR-PET) procedures in the opinion of the Investigator.
  13. Patients must also have a genotype associated with a high or mixed affinity translocator protein (TSPO) (Ala/Ala or Ala/Thr) and ability to safely undergo MR-PET scans based on the opinion of the Investigator.

Exclusion Criteria:

  1. Dependence on invasive or non-invasive ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use; presence of tracheostomy at screening; or presence of diaphragm pacing system at screening.
  2. Exposure to any experimental treatment for ALS within the last 30 days or five half-lives, whichever is longer.
  3. Treatment within 12 months with immunomodulator or immunosuppressant agent (including but not limited to cyclophosphamide, cyclosporine, interferon-α, interferon-β-1a, rituximab, alemtuzumab, azathioprine, etanercept, infliximab, adalimumab, certolizumab, golimumab, anakinra, rilonacept, secukinumab, tocilizumab, mycophenolate mofetil, methotrexate, cell-depleting agents, total lymphoid irradiation, dimethyl fumarate). Treatment with intravenous immunoglobulin (IVIG) within 2 months. Non-steroidal anti-inflammatory drugs (NSAIDs) are acceptable.
  4. Exposure at any time to any cell or gene therapies under investigation for the treatment of ALS.
  5. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other opportunistic infections; or major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 4 weeks.
  6. Live-attenuated vaccines within 30 days before dosing. Subjects must agree to forego live-attenuated vaccines throughout the study, including 60 days after the last dose of study drug.
  7. History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies.
  8. History of one or more of the following: cardiac insufficiency (New York Heart Association [NYHA] III/IV), uncontrolled cardiac arrhythmias, unstable ischemic heart disease, or uncontrolled hypertension (systolic blood pressure > 170 mmHg or diastolic blood pressure > 110 mmHg).
  9. History of myocardial infarction, or cerebrovascular accident.
  10. Unstable pulmonary, renal, hepatic, endocrine or hematologic disease.
  11. Autoimmune disease, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to rheumatoid arthritis.
  12. Evidence of active malignant disease, malignancies diagnosed within the previous 5 years, or breast cancer diagnosed within the previous 5 years (except skin cancers other than melanoma).
  13. History of human immunodeficiency virus infection or other immunodeficiency illness.
  14. Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days.
  15. History of drug abuse (not including marijuana use) or alcoholism within the past 12 months.
  16. Significant neuromuscular disease other than ALS.
  17. Other ongoing disease that may cause neuropathy, such as toxin exposure, dietary deficiency, uncontrolled diabetes, hyperthyroidism, cancer, systemic lupus erythematosus or other connective diseases, infection with HIV, hepatitis B virus (HBV), or hepatitis C (HCV), Lyme disease, multiple myeloma, Waldenström's macroglobulinemia, amyloid, and hereditary neuropathy.
  18. Pregnancy or breastfeeding.
  19. Deprivation of freedom by administrative or court order.
  20. Any contraindication to undergo magnetic resonance imaging (MRI) studies such as history of a cardiac pacemaker or pacemaker wires; metallic particles in the body; vascular clips in the head; prosthetic heart valves; or severe claustrophobia.
  21. Unwilling or unable to discontinue benzodiazepine usage [other than lorazepam (Ativan®), clonazepam (Klonopin®), or zolpidem (Ambien®)] for one day prior to and during scanning.
  22. Research imaging-related radiation exposure exceeds current institutional Radiology Department guidelines

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03474263

Contact: Jan Agosti, MD (206)619-9963

United States, Massachusetts
Neurological Clinical Research Institute (NCRI) Not yet recruiting
Boston, Massachusetts, United States, 02114
Contact: Nazem Atassi, MD, MMSc    617-643-6114   
Sponsors and Collaborators
Implicit Bioscience
Massachusetts General Hospital
Principal Investigator: Nazem Atassi, MD, MMSc Massachusetts General Hospital

Responsible Party: Implicit Bioscience Identifier: NCT03474263     History of Changes
Other Study ID Numbers: ALS02
First Posted: March 22, 2018    Key Record Dates
Last Update Posted: April 18, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Implicit Bioscience:
Motor Neurone Disease (MND)
Amyotrophic Lateral Sclerosis (ALS)

Additional relevant MeSH terms:
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
Metabolic Diseases
Pathologic Processes
TDP-43 Proteinopathies
Proteostasis Deficiencies
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs